Bayer Aktienges Ads (BAYRY) 132.9800 $BAYRY
Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
Boston Scientific Poised on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 1:50PM CDT
Boston Scientific's second-quarter 2014 adjusted EPS of 21 cents beat the year-ago figure by 16.7% and exceeded the company's guided range.
Cannabis Therapy Corp Extends Strategic Plan Into Cannabinoid Products for Animal Health
ACCESSWIRE - Thu Aug 14, 11:48AM CDT
Whitefish, MT / August 14, 2014 / From spending on cardiology to oncology to specialty foods, people love their pets and religiously earmark income for requisite and discretionary spending on their furry friends. This is evident through industry expert American Pet Products stating overall expenditures in the pet industry climbed from $43.2 billion in 2008 to $55.72 billion in 2013. Not even the 2009-2013 Great Recession caused consumers to hit the brakes hard on allocating cash for their pets. The largest chunk of the overall spending went to food ($22.6 billion), followed by the veterinary care category ($15.3 billion) and then supplies/Over-the-Counter medicine ($13.7 billion). As noted by Embrace Pet Insurance, the supplies/OTC meds category remains robust, with their analysts estimating that growth in this sector outpaced the 6.7% expansion forecast by American Pet Products in 2013.
Polymeric Polyols - Global Strategic Business Report
PR Newswire Europe - Thu Aug 14, 8:57AM CDT
Research and Markets [http://www.researchandmarkets.com/research/rc8h67/polymeric_polyols] has announced the addition of the "Polymeric Polyols - Global Strategic Business Report" [http://www.researchandmarkets.com/research/rc8h67/polymeric_polyols] report to their offering.
Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:20PM CDT
Regeneron's (REGN) Eylea has been approved for a third indication in the EU.
Research and Markets: Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
Business Wire - Tue Aug 12, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqtw8n/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering.
Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Aug 12, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6chxqf/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering. The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018. NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period. Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide. The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Alcon Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - iCo Therapeutics Inc. - Pfizer Inc. - Santen Pharmaceutical Co. Ltd. For more information visit http://www.researchandmarkets.com/research/6c...al_macular
U.S. Antimicrobial Plastics Market - Industry Analysis 2014 - 2020 (Appliances, Personal Care, Packaging, Automotive, Building & Construction, Healthcare)
M2 - Mon Aug 11, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6gfj6/u_s) has announced the addition of the "U.S. Antimicrobial Plastics Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Antimicrobial plastics are molded polymers infused with antimicrobials to inhibit the growth of various harmful microorganisms such as fungi and bacteria. Antimicrobial plastics are used in various industries such as healthcare, automotives, building & construction, electronics, packaging and consumer goods. Additionally, they are used in niche applications such as pipes, plastic water storage containers, waste bins and lids. Rising awareness among consumers regarding good health and cleanliness is expected to be one of the primary factors driving the growth of the antimicrobial plastics market. The report on U.S.antimicrobial plastics market report forecasts and analyzes the antimicrobial plastics market on a regional level. The forecast demand on the global level is based on volume (tons) and revenue (USD million) for the period ranging from 2014 to 2020. The study on U.S. antimicrobial plastics market outlines drivers and restraints of the polyester market and their impact on market growth during the mentioned time period. Additionally, the study includes opportunities available for the market on the regional and level and their effect during the said forecast period. All plastics infused with antimicrobials have been classified as antimicrobial plastics under the scope of this study. Personal care includes packaging of personal care products. Packaging of healthcare products has been classified under the packaging segment. Packaging typically includes foods, beverages and pharmaceuticals. In other words, the segment includes all types of packaging, except for personal care products. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Antimicrobial Plastics - Industry Analysis Chapter 4 Antimicrobial Plastics Market - Application Analysis Chapter 5 Company Profiles Companies Mentioned - AkzoNobel N.V. - BASF SE - Bayer AG - Diamond Vogel - E. I. du Pont de Nemours and Company - Ishizuka Glass Co. Ltd. - Lonza Group AG - Momentive Performance Materials Inc. - Sciessent LLC - Sherwin-Williams - Sinanen Zeomic Co Ltd - Teknor Apex - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/j6gfj6/u_s
Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 2:02PM CDT
Regeneron (REGN) recorded higher than expected revenues due to strong Eylea sales.
Bayer Corporation Donates $100,000 to the American Red Cross to Support Disaster and Emergency Preparedness
PR Newswire - Tue Aug 05, 7:00AM CDT
Bayer Corporation today announced a $100,000 donation to the American Red Cross to support the organization's national disaster and emergency preparedness efforts across the United States.
Bayer Earnings Grow Marginally Y/Y, New Products Encourage - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:41AM CDT
Bayer's (BAYRY) newly launched products performed well in the quarter.
Global Acaricides Market - Forecasts to 2019
M2 - Thu Jul 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdkmx2/acaricides_market) has announced the addition of the "Acaricides Market by Type, by Application, by Mode of Action & Geography - Trends & Forecasts to 2019" report to their offering. Chemicals that are used to kill ticks and mites are known as acaricides. They help in increasing productivity by keeping animals and crops healthy and disease-free. Cattle, when treated with acaricides are less susceptible to tick-borne diseases and there is an increase in the milk and other product yield. The acaricides market is growing steadily due to increase in the demand of the crops and animal products. Factors that act as driving forces for this market are the increase in productivity, development in the crop protection industry, and the growing demand of crops and animal products across the world. The high cost of raw materials and the strict regulatory norms imposed by some governments pose as hindrances for this market. Various secondary sources such as encyclopedias, directories, and databases, were used to identify and collect information useful for this extensive market-oriented study of the acaricides market. The primary sources-experts from related industries and suppliers-were interviewed to obtain and verify critical information as well as to assess the future prospects of the global acaricides market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Analysis 5 Market Overview 6 Industry Analysis 7 Acaricides Market, By Type 8 Acaricides Market, By Application 9 Acaricides Market, By Mode of Action 10 Acaricides Market, By Geography 11 Competitive Landscape 12 Company Profile Companies Mentioned: - Arysta Lifescience - BASF SE - Bayer AG - Chemtura Corporation - Dupont - FMC Corporation - Merck & Co., Inc. - Nissan Chemical Industries, Ltd. - Syngenta AG - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/bd...des_market
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.
Amgen Restructuring Plan, Q2 Earnings Send Stock Up
at Investor's Business Daily - Wed Jul 30, 10:20AM CDT
Amgen (AMGN) was up more than 5%, near 129, in early trading in the stock market today as analysts approved of big-cap biotech's earnings beat and restructuring plans announced late Tuesday. Earlier, Amgen stock touched a new high above 131. Amgen's...
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
European Stocks Steady as Barclays Reports, AstraZeneca Buys Generic Line
at The Street - Wed Jul 30, 5:31AM CDT
European stock indices were little changed on Wednesday as a new round of U.S. and European Union sanctions against Russia over Ukraine coincided with a slew of corporate earnings.
Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...
Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
Boston Scientific Poised on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 1:50PM CDT
Boston Scientific's second-quarter 2014 adjusted EPS of 21 cents beat the year-ago figure by 16.7% and exceeded the company's guided range.
Cannabis Therapy Corp Extends Strategic Plan Into Cannabinoid Products for Animal Health
ACCESSWIRE - Thu Aug 14, 11:48AM CDT
Whitefish, MT / August 14, 2014 / From spending on cardiology to oncology to specialty foods, people love their pets and religiously earmark income for requisite and discretionary spending on their furry friends. This is evident through industry expert American Pet Products stating overall expenditures in the pet industry climbed from $43.2 billion in 2008 to $55.72 billion in 2013. Not even the 2009-2013 Great Recession caused consumers to hit the brakes hard on allocating cash for their pets. The largest chunk of the overall spending went to food ($22.6 billion), followed by the veterinary care category ($15.3 billion) and then supplies/Over-the-Counter medicine ($13.7 billion). As noted by Embrace Pet Insurance, the supplies/OTC meds category remains robust, with their analysts estimating that growth in this sector outpaced the 6.7% expansion forecast by American Pet Products in 2013.
Polymeric Polyols - Global Strategic Business Report
PR Newswire Europe - Thu Aug 14, 8:57AM CDT
Research and Markets [http://www.researchandmarkets.com/research/rc8h67/polymeric_polyols] has announced the addition of the "Polymeric Polyols - Global Strategic Business Report" [http://www.researchandmarkets.com/research/rc8h67/polymeric_polyols] report to their offering.
Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:20PM CDT
Regeneron's (REGN) Eylea has been approved for a third indication in the EU.
Research and Markets: Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
Business Wire - Tue Aug 12, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqtw8n/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering.
Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Aug 12, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6chxqf/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering. The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018. NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period. Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide. The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Alcon Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - iCo Therapeutics Inc. - Pfizer Inc. - Santen Pharmaceutical Co. Ltd. For more information visit http://www.researchandmarkets.com/research/6c...al_macular
U.S. Antimicrobial Plastics Market - Industry Analysis 2014 - 2020 (Appliances, Personal Care, Packaging, Automotive, Building & Construction, Healthcare)
M2 - Mon Aug 11, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6gfj6/u_s) has announced the addition of the "U.S. Antimicrobial Plastics Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Antimicrobial plastics are molded polymers infused with antimicrobials to inhibit the growth of various harmful microorganisms such as fungi and bacteria. Antimicrobial plastics are used in various industries such as healthcare, automotives, building & construction, electronics, packaging and consumer goods. Additionally, they are used in niche applications such as pipes, plastic water storage containers, waste bins and lids. Rising awareness among consumers regarding good health and cleanliness is expected to be one of the primary factors driving the growth of the antimicrobial plastics market. The report on U.S.antimicrobial plastics market report forecasts and analyzes the antimicrobial plastics market on a regional level. The forecast demand on the global level is based on volume (tons) and revenue (USD million) for the period ranging from 2014 to 2020. The study on U.S. antimicrobial plastics market outlines drivers and restraints of the polyester market and their impact on market growth during the mentioned time period. Additionally, the study includes opportunities available for the market on the regional and level and their effect during the said forecast period. All plastics infused with antimicrobials have been classified as antimicrobial plastics under the scope of this study. Personal care includes packaging of personal care products. Packaging of healthcare products has been classified under the packaging segment. Packaging typically includes foods, beverages and pharmaceuticals. In other words, the segment includes all types of packaging, except for personal care products. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Antimicrobial Plastics - Industry Analysis Chapter 4 Antimicrobial Plastics Market - Application Analysis Chapter 5 Company Profiles Companies Mentioned - AkzoNobel N.V. - BASF SE - Bayer AG - Diamond Vogel - E. I. du Pont de Nemours and Company - Ishizuka Glass Co. Ltd. - Lonza Group AG - Momentive Performance Materials Inc. - Sciessent LLC - Sherwin-Williams - Sinanen Zeomic Co Ltd - Teknor Apex - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/j6gfj6/u_s
Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 2:02PM CDT
Regeneron (REGN) recorded higher than expected revenues due to strong Eylea sales.
Bayer Corporation Donates $100,000 to the American Red Cross to Support Disaster and Emergency Preparedness
PR Newswire - Tue Aug 05, 7:00AM CDT
Bayer Corporation today announced a $100,000 donation to the American Red Cross to support the organization's national disaster and emergency preparedness efforts across the United States.
Bayer Earnings Grow Marginally Y/Y, New Products Encourage - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:41AM CDT
Bayer's (BAYRY) newly launched products performed well in the quarter.
Global Acaricides Market - Forecasts to 2019
M2 - Thu Jul 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdkmx2/acaricides_market) has announced the addition of the "Acaricides Market by Type, by Application, by Mode of Action & Geography - Trends & Forecasts to 2019" report to their offering. Chemicals that are used to kill ticks and mites are known as acaricides. They help in increasing productivity by keeping animals and crops healthy and disease-free. Cattle, when treated with acaricides are less susceptible to tick-borne diseases and there is an increase in the milk and other product yield. The acaricides market is growing steadily due to increase in the demand of the crops and animal products. Factors that act as driving forces for this market are the increase in productivity, development in the crop protection industry, and the growing demand of crops and animal products across the world. The high cost of raw materials and the strict regulatory norms imposed by some governments pose as hindrances for this market. Various secondary sources such as encyclopedias, directories, and databases, were used to identify and collect information useful for this extensive market-oriented study of the acaricides market. The primary sources-experts from related industries and suppliers-were interviewed to obtain and verify critical information as well as to assess the future prospects of the global acaricides market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Analysis 5 Market Overview 6 Industry Analysis 7 Acaricides Market, By Type 8 Acaricides Market, By Application 9 Acaricides Market, By Mode of Action 10 Acaricides Market, By Geography 11 Competitive Landscape 12 Company Profile Companies Mentioned: - Arysta Lifescience - BASF SE - Bayer AG - Chemtura Corporation - Dupont - FMC Corporation - Merck & Co., Inc. - Nissan Chemical Industries, Ltd. - Syngenta AG - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/bd...des_market
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.
Amgen Restructuring Plan, Q2 Earnings Send Stock Up
at Investor's Business Daily - Wed Jul 30, 10:20AM CDT
Amgen (AMGN) was up more than 5%, near 129, in early trading in the stock market today as analysts approved of big-cap biotech's earnings beat and restructuring plans announced late Tuesday. Earlier, Amgen stock touched a new high above 131. Amgen's...
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
European Stocks Steady as Barclays Reports, AstraZeneca Buys Generic Line
at The Street - Wed Jul 30, 5:31AM CDT
European stock indices were little changed on Wednesday as a new round of U.S. and European Union sanctions against Russia over Ukraine coincided with a slew of corporate earnings.
Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...
